Creative Planning Buys 27,114 Shares of Denali Therapeutics Inc. $DNLI

Creative Planning increased its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 88.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,678 shares of the company’s stock after purchasing an additional 27,114 shares during the period. Creative Planning’s holdings in Denali Therapeutics were worth $807,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in DNLI. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Denali Therapeutics by 15.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after buying an additional 753 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after acquiring an additional 1,551 shares during the last quarter. Empowered Funds LLC grew its holdings in Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock valued at $281,000 after purchasing an additional 2,052 shares during the period. E Fund Management Co. Ltd. increased its stake in Denali Therapeutics by 20.7% in the first quarter. E Fund Management Co. Ltd. now owns 12,069 shares of the company’s stock valued at $164,000 after purchasing an additional 2,072 shares in the last quarter. Finally, Breakwater Capital Group increased its stake in Denali Therapeutics by 13.9% in the second quarter. Breakwater Capital Group now owns 17,096 shares of the company’s stock valued at $239,000 after purchasing an additional 2,081 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Down 6.7%

Shares of Denali Therapeutics stock opened at $18.16 on Tuesday. The firm has a market cap of $2.66 billion, a PE ratio of -6.24 and a beta of 1.11. The business’s 50 day simple moving average is $16.22 and its 200 day simple moving average is $14.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $26.18.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.02. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.63) EPS. On average, analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DNLI. Stifel Nicolaus set a $37.00 price target on shares of Denali Therapeutics in a report on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Denali Therapeutics in a report on Monday, September 8th. Morgan Stanley cut their price objective on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, August 18th. Finally, JPMorgan Chase & Co. boosted their price objective on Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $32.64.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.